Patients with pathological high-risk stage II and stage III colorectal cancer after radical resection were randomly allocated to receive thymosin-alpha 1 twice a week for 6 months (experimental group) or not (control group) in a 1:1 ratio. At the same time, all patients will receive chemo/radiotherapy according to the Chinese Standards for Diagnosis and Treatment of Colorectal Cancer. The primary endpoint is 3-year DFS rate.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Colorectal cancer receiving radical resection
Pathologically diagnosed with high-risk stage II or stage III
Eastern Cooperative Oncology Group performance status of 0-2
Adequate hepatic, renal, and hematologic function
You may not be if
Had previously taken any immune-promoting drugs
Pregnancy or lactation
Clareo Health | Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
